Page 1 | Search Results | Blood | American Society of Hematology

1-10 of 10

Sort by

Sort Order Select

Journal Articles

Single-cell analysis reveals immune dysfunction from the earliest stages of CLL that can be reversed by ibrutinib

Blood (2022) 139 (14): 2252–2256.

https://doi.org/10.1182/blood.2021013926

Published: 2022

Includes: Supplemental data

Journal Articles

Targeted Deep Sequencing in Untreated Progressive CLL Helps to Better Dissect the Genomic Landscape and Shows Novel Associations between Mutations, Prognostic and Clinical Parameters: Data from E1912, a Randomized Phase III Study of the ECOG-ACRIN Cancer Research Group

Esteban Braggio, PhD, Victoria Wang, Laura Ann Bruins, BS, Santiago Barrio, PhD, Connie Lesnick, Jacqueline C. Barrientos, MD, Susan M. O'Brien, MD, Martin S. Tallman, MD, Mark R. Litzow, MD, Rafael Fonseca, MD, Neil E. Kay, MD, Tait D Shanafelt, MD

Blood (2017) 130 (Supplement 1): 4288.

https://doi.org/10.1182/blood.V130.Suppl_1.4288.4288

Published: 2017

Journal Articles

Novel Associations Between Mutations, Prognostic and Clinical Parameters in Untreated Progressive CLL: Data from E1912, a Randomized Phase III Study of the ECOG-ACRIN Cancer Research Group

Esteban Braggio, PhD, Victoria X Wang, Santiago Garcia, PhD, Laura Ann Bruins, Connie Lesnick, Jacqueline C. Barrientos, MD, Susan M. O'Brien, MD, Martin S. Tallman, MD, Rafael Fonseca, MD, Neil E. Kay, MD, Tait D. Shanafelt, MD

Blood (2016) 128 (22): 4373.

https://doi.org/10.1182/blood.V128.22.4373.4373

Published: 2016

Journal Articles

Targeted Inhibition of Axl Primes Chronic Lymphocytic Leukemia B-Cells for Apoptosis: Synergistic/Additive Effects in Combination with Bruton Tyrosine Kinase Inhibitors

Sutapa Sinha, PhD, Justin Boysen, Michael Nelson, Charla Secreto, Steven L. Warner, PhD, David J. Bearss, PhD, Connie Lesnick, M.Sc, Tait D. Shanafelt, MD, Neil E. Kay, MD, Asish K Ghosh, PhD

Blood (2014) 124 (21): 1946.

https://doi.org/10.1182/blood.V124.21.1946.1946

Published: 2014

Journal Articles

Activated Chronic Lymphocytic Leukemia B-Cells Preferentially Shed CD52 + Microvesicles, but Not CD19 + , and May Predict Therapeutic Outcome

Sutapa Sinha, PhD, Justin Boysen, Michael Nelson, Connie Lesnick, M.Sc, Tait D. Shanafelt, MD, Neil E. Kay, MD, Asish K Ghosh, PhD

Blood (2014) 124 (21): 1961.

https://doi.org/10.1182/blood.V124.21.1961.1961

Published: 2014

Journal Articles

The AKT Inhibitor MK2206 In Combination With Rituximab and Bendamustine Is Tolerable and Active In Relapsed Or Refractory Chronic Lymphocytic Leukemia: Results From a Phase 1 Study (NCCTG N1087 Alliance)

Wei Ding, MD, PhD, Tait D Shanafelt, MD, Clive S. Zent, MD, Jose F. Leis, MD, PhD, Betsy R. LaPlant, Timothy G. Call, MD, Curtis A Hanson, MD, Charles Erlichman, MD, Thomas M. Habermann, MD, Craig Reeder, MD, Daniel Nikcevich, Deborah Bowen, CNP, Michael J. Conte, PA-C, Justin Boysen, Charla Secreto, Connie Lesnick, M.Sc, Renee C. Tschumper, Diane F. Jelinek, PhD, Neil E. Kay, MD

Blood (2013) 122 (21): 2882.

https://doi.org/10.1182/blood.V122.21.2882.2882

Published: 2013

Journal Articles

Novel Pharmacological Agents Differentially Modulate Cytokine Release On CLL B-Cell-Stromal Cell Co-Culture: Implications for Stromal Rescue of CLL B-Cells From Chemotherapy

Connie Lesnick, M.Sc, Asish K Ghosh, PhD, Betsy R. LaPlant, Wei Ding, MD, PhD, Neil E. Kay, MD, Tait D. Shanafelt, MD

Blood (2012) 120 (21): 3927.

https://doi.org/10.1182/blood.V120.21.3927.3927

Published: 2012

Journal Articles

Allosteric Akt Inhibitor MK2206 Synergizes with Bendamustine in Promoting the Apoptosis of Chronic Lymphocytic Leukemia Cells and Selectively Targets B-Cell Receptor Mediated Cytokine Production

Wei Ding, MD, PhD, Tait D. Shanafelt, MD, Connie Lesnick, M.Sc, Traci Sassoon, Charla Secreto, Charles Erlichman, MD, Jose Leis, MD, PhD, Timothy G. Call, MD, Deborah Bowen, CNP, Shaji K. Kumar, MD, Neil E. Kay, MD

Blood (2012) 120 (21): 3928.

https://doi.org/10.1182/blood.V120.21.3928.3928

Published: 2012

Journal Articles

Epigallocatechin-3-Gallate (EGCG) Modulates Cytokine Production When Leukemic CLL B-Cells and Marrow Stromal Cells Are Co-Cultured: Correlations with Clinical Activity in a Phase II Trial,

Connie Lesnick, Neil Kay, MD, Betsy R. LaPlant, Asish K Ghosh, PhD, Tait D. Shanafelt, MD

Blood (2011) 118 (21): 3882.

https://doi.org/10.1182/blood.V118.21.3882.3882

Published: 2011

Journal Articles

The Green Tea Extract EGCG Demonstrates Synergist Activity against CLL B-Cells When Combined with Fludarabine and Chlorambucil.

Connie Lesnick, Neil E. Kay, MD, Betsy LaPlant, Tait D. Shanafelt, M.D.,

Blood (2009) 114 (22): 3452.

https://doi.org/10.1182/blood.V114.22.3452.3452

Published: 2009

NARROW

Single-cell analysis reveals immune dysfunction from the earliest stages of CLL that can be reversed by ibrutinib

Targeted Deep Sequencing in Untreated Progressive CLL Helps to Better Dissect the Genomic Landscape and Shows Novel Associations between Mutations, Prognostic and Clinical Parameters: Data from E1912, a Randomized Phase III Study of the ECOG-ACRIN Cancer Research Group

Novel Associations Between Mutations, Prognostic and Clinical Parameters in Untreated Progressive CLL: Data from E1912, a Randomized Phase III Study of the ECOG-ACRIN Cancer Research Group

Targeted Inhibition of Axl Primes Chronic Lymphocytic Leukemia B-Cells for Apoptosis: Synergistic/Additive Effects in Combination with Bruton Tyrosine Kinase Inhibitors

Activated Chronic Lymphocytic Leukemia B-Cells Preferentially Shed CD52 + Microvesicles, but Not CD19 + , and May Predict Therapeutic Outcome

The AKT Inhibitor MK2206 In Combination With Rituximab and Bendamustine Is Tolerable and Active In Relapsed Or Refractory Chronic Lymphocytic Leukemia: Results From a Phase 1 Study (NCCTG N1087 Alliance)

Novel Pharmacological Agents Differentially Modulate Cytokine Release On CLL B-Cell-Stromal Cell Co-Culture: Implications for Stromal Rescue of CLL B-Cells From Chemotherapy

Allosteric Akt Inhibitor MK2206 Synergizes with Bendamustine in Promoting the Apoptosis of Chronic Lymphocytic Leukemia Cells and Selectively Targets B-Cell Receptor Mediated Cytokine Production

Epigallocatechin-3-Gallate (EGCG) Modulates Cytokine Production When Leukemic CLL B-Cells and Marrow Stromal Cells Are Co-Cultured: Correlations with Clinical Activity in a Phase II Trial,

The Green Tea Extract EGCG Demonstrates Synergist Activity against CLL B-Cells When Combined with Fludarabine and Chlorambucil.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only